Johnson and Johnson Loses Key Tuberculosis Drug Patent in India
1 year, 9 months ago

Johnson and Johnson Loses Key Tuberculosis Drug Patent in India

News 18  

India’s Patent Office rejected on Thursday US pharmaceutical giant Johnson and Johnson’s application to extend its patent on a key tuberculosis treatment, allowing local companies to make cheaper generic versions. India accounted for nearly 29 percent of 10.6 million tuberculosis cases worldwide, according to the World Health Organization’s 2022 Global TB report, a major public health problem as it struggles with drug-resistant strains. Johnson and Johnson had applied to extend its patent on the drug bedaquiline until 2027 after it was challenged by two tuberculosis survivors in Mumbai in 2019. “ urge generic manufacturers to use this opportunity to enter the market and produce and supply quality-assured generic versions of the lifesaving TB drug bedaquiline without the fear of litigation hanging over their heads,” Ilaria Motta, tuberculosis medical adviser for the MSF Access Campaign, said in a statement.

India Patent Johnson Drug Tuberculosis Its Patent  manufacturers  extend  drug  key  generic  johnson  bedaquiline  welcomed  loses  india  patent  tuberculosis  tb

History of this topic

India paves way for a cheaper anti-tuberculosis drug for kids
5 months ago

India paves way for a cheaper anti-tuberculosis drug for kids

Hindustan Times  

The Indian Patent Office’s rejection of Johnson & Johnson’s application for the paediatric version of its anti-tuberculosis drug, bedaquiline, is likely to have broader implications for access to cost-effective TB treatment, according to experts. Last year, the patent office also rejected the US pharmaceutical corporation’s attempt to extend its monopoly in India on bedaquiline for treating adults beyond the primary …

South Africa, Colombia and others are fighting drugmakers over access to TB and HIV drugs
1 year, 1 month ago

South Africa, Colombia and others are fighting drugmakers over access to TB and HIV drugs

Associated Press  

CAPE TOWN, South Africa — South Africa, Colombia and other countries that lost out in the global race for coronavirus vaccines are taking a more combative approach towards drugmakers and pushing back on policies that deny cheap treatment to millions of people with tuberculosis and HIV. In the COVID-19 pandemic, rich countries bought most of the world’s vaccines early, leaving …

Explained | Will generic supply of bedaquiline be accessible?
1 year, 5 months ago

Explained | Will generic supply of bedaquiline be accessible?

The Hindu  

The story so far: Bedaquiline has now become the cornerstone to cure drug-resistant tuberculosis. Last week, a major barrier for drug resistant TB care ended, when Johnson & Johnson’s patent on bedaquiline expired on July 18. This long-awaited expiry will allow generic manufacturers to supply the drug, but J&J appears intent on maintaining its monopoly over the bedaquiline market. Indian …

Johnson and Johnson shares licence for tuberculosis drug after novelist’s viral campaign
1 year, 5 months ago

Johnson and Johnson shares licence for tuberculosis drug after novelist’s viral campaign

The Independent  

The latest headlines from our reporters across the US sent straight to your inbox each weekday Your briefing on the latest headlines from across the US Please enter a valid email address Please enter a valid email address SIGN UP I would like to be emailed about offers, events and updates from The Independent. Please try again later {{ /verifyErrors …

Explained | Bedaquiline, India’s anti-tuberculosis fight, and a patent battle
1 year, 8 months ago

Explained | Bedaquiline, India’s anti-tuberculosis fight, and a patent battle

The Hindu  

The story so far: On March 23, the Indian Patent Office rejected an application by pharmaceutical giant Johnson & Johnson to extend its patent on the drug bedaquiline beyond July 2023. The rejection opens the door for drug manufacturers to produce generic versions of bedaquiline, which are expected to be more affordable and to contribute to India’s goal of eliminating …

India Rejects J&J Plea to Extend Patent on Key Tuberculosis Drug, Drop in Prices Expected
1 year, 9 months ago

India Rejects J&J Plea to Extend Patent on Key Tuberculosis Drug, Drop in Prices Expected

News 18  

In a massive blow, the Indian Patent Office rejected US pharmaceutical giant Johnson & Johnson’s application to extend its monopoly on the key tuberculosis drug, bedaquiline, which is set to expire in July. Developed by Janssen – Johnson & Johnson’s pharmaceutical division – in 2012, bedaquiline received conditional approval by the US Food and Drug Administration for the treatment of …

India rejects Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug
1 year, 9 months ago

India rejects Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug

The Hindu  

In a victory for patients fighting for wider access to crucial anti-tuberculosis drug Bedaquiline, the Indian Patent Office on Thursday rejected U.S. pharmaceutical giant Johnson & Johnson’s attempt to extend its monopoly on manufacturing the drug in India beyond July 2023. J&J’s primary patents on Bedaquiline expire in July, paving the way for generic drug manufacturers such as Lupin and …

Final hearing in tuberculosis drug patent case ends, verdict likely in a month
1 year, 10 months ago

Final hearing in tuberculosis drug patent case ends, verdict likely in a month

Hindustan Times  

New Delhi: The Indian Patent Office had held its final hearing on a challenge filed by two tuberculosis survivors to prevent the Indian arm of drugmaker Johnson & Johnson from extending its patent on bedaquiline, used against drug-resistant TB, beyond the primary patent’s expiry in July. Final hearing in tuberculosis drug patent case ends, verdict likely in a month If …

Discover Related